Introduction to the BCI Landscape

**Invasive BCI technology** is at the forefront of modern neurological rehabilitation and neurosurgery. Recently, the Beijing-backed startup NeuCyber Neurotech admitted that its latest developments trail Elon Musk's Neuralink by approximately three years. Although China has made significant regulatory strides, the gap in clinical data remains substantial. Consequently, researchers are accelerating efforts to expand animal testing and early-feasibility trials. This competitive landscape highlights the global push to restore motor function in paralyzed patients through advanced neural implants.

Breakthroughs in Invasive BCI Technology

Neuralink currently leads the field with its N1 chip and specialized surgical robot. This robot can insert hundreds of electrodes into the brain with extreme precision within minutes. Meanwhile, NeuCyber is currently focused on its Beinao-2 product, which uses flexible electrodes for full implantation. However, this device is still undergoing large-scale animal testing before it can enter human clinical trials. Specifically, the company expects to reach the formal trial phase in about two years. Furthermore, the goal is to refine motor function restoration for those suffering from severe spinal cord injuries.

Clinical Progress and Regulatory Approvals

In a historic move, China recently became the first country to approve an invasive BCI device for commercial use. This device, developed by the private firm Neuracle, helps patients with spinal cord injuries control robotic gloves. Additionally, NeuCyber has successfully performed seven human implantations of its earlier Beinao-1 model. These quadriplegic survivors reported significant improvements in hand function and computer cursor control after six months. Moreover, the firm hopes to expand these trials to 50 patients within the year. Such an expansion could potentially give China the highest number of BCI patients globally. Nevertheless, Neuralink maintains a clinical advantage with over 21 participants enrolled worldwide as of early 2026.

Frequently Asked Questions

Q1: What is the main difference between NeuCyber's Beinao-1 and Beinao-2?

Beinao-1 is a semi-invasive BCI consisting of a mesh with electrodes placed on the brain's outer membrane. In contrast, Beinao-2 is a fully invasive BCI with flexible electrodes that implant directly into the brain tissue, similar to the Neuralink N1 chip.

Q2: Why does Neuralink have a perceived three-year advantage over NeuCyber?

The lag is primarily due to the volume of human clinical data. Neuralink has already successfully implanted devices in over 20 patients and utilizes an automated surgical robot for electrode insertion, whereas NeuCyber's most advanced model is still in the animal testing phase.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.

References

1. Beijing-backed brain chip firm says it is 3 years behind Musk's Neuralink - ETHealthworld


2. Medical Device Network. (2026). Neuracle Technology receives China's NMPA clearance for BCI device.


3. South China Morning Post. (2026). In a first for China, Neuracle's implantable brain-computer interface wins approval.